Oxford Gene Technology (OGT) will launch its new CytoSure™ Consortium Cancer +SNP array (4x180k) at the Cancer Cytogenomics Microarray Consortium (CCMC) and Cytogenomics Array Group (CAGdb) combined meeting in Chicago on the 5th- 7th August, booth 4.
The new CytoSure™ Consortium Cancer +SNP array allows the simultaneous detection of copy number variation (CNV) and loss of heterozygosity (LOH), with a SNP resolution that enables reporting of LOH at 10Mb. Focusing on content recommended by the CCMC, an international organisation of clinical cytogeneticists, molecular cytogeneticists and molecular pathologists, this targeted array covers over 500 cancer genes and 130 cancer-associated genomic regions for haematological malignancies and solid tumours. The CCMC-approved standardised array design is intended to improve clinical research quality and promotes collaboration and communication between cancer cytogenomics laboratories.
The new array will be the latest addition to a range of OGT microarrays specifically designed for detecting CNV and LOH on a single array for cancer research. This includes the recently released CytoSure Cancer +SNP array (4x180k) covering 1500 cancer associated genes and the CytoSure Haematological Cancer + SNP array (8x60k) focused specifically on haematological cancers. Due to the unique design of OGT’s SNP probes, there are no changes to the standard aCGH protocol, no restriction digest is required and any reference sample can be used. This enables the use of matched samples which is a particular advantage in cancer research, allowing constitutional abnormalities to be filtered out. For effortless data analysis, OGT’s CytoSure Interpret Software is supplied with all CytoSure arrays and delivers reliable and user-friendly data analysis, providing rapid access to meaningful results.
James Clough, Executive Vice President Commercial at OGT, said: “The new CytoSure Consortium Cancer +SNP array is part of OGT’s commitment to advancing the field of cytogenetic cancer research. OGT’s collaborations in the design and development of our arrays with international organisations such as the CCMC who are leaders in cancer cytogenetics research, are testament to this. By providing reliable, high-quality CNV and SNP detection for haematological malignancies and solid cancers, these arrays are valuable tools for accurately and efficiently defining the genetic nature of cancers, advancing research into novel and improved therapeutics”.
Delegates of the CCMC / CAGdb meeting can find out more about OGT’s expertise in cancer cytogenetics by attending a talk by Ephrem Chin, Regional Sales manager at OGT, entitled ‘Oxford Gene Technology – Meeting laboratory needs’. The talk will be presented as part of the ‘Data quality and QC metrics’ workshop at 1 – 3pm on the 6th August and provides an opportunity for researchers to share in OGT’s extensive experience in high-throughput array processing and associated QC metrics and data analysis.
OGT representatives will also be available at booth 4 for the duration of the meeting.